Ovid Therapeutics Inc.OVIDNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+259.3%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+259.3%/yr
Quarterly compound
Percentile
P97
Near historical high
vs 3Y Ago
46.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 179.49% |
| Q3 2025 | -159.56% |
| Q2 2025 | 54.24% |
| Q1 2025 | -10.61% |
| Q4 2024 | 33.94% |
| Q3 2024 | -264.37% |
| Q2 2024 | 172.87% |
| Q1 2024 | 23.68% |
| Q4 2023 | -36.16% |
| Q3 2023 | 9.31% |
| Q2 2023 | 7.10% |
| Q1 2023 | -16.09% |
| Q4 2022 | 3.87% |
| Q3 2022 | 17.96% |
| Q2 2022 | 9.43% |
| Q1 2022 | 35.95% |
| Q4 2021 | -120.92% |
| Q3 2021 | 27.89% |
| Q2 2021 | -108.97% |
| Q1 2021 | 898.96% |
| Q4 2020 | -34.12% |
| Q3 2020 | 27.17% |
| Q2 2020 | -12.59% |
| Q1 2020 | -18.04% |
| Q4 2019 | -2.01% |
| Q3 2019 | -27.40% |
| Q2 2019 | 5.38% |
| Q1 2019 | -6.98% |
| Q4 2018 | 0.48% |
| Q3 2018 | -0.21% |
| Q2 2018 | 1.88% |
| Q1 2018 | -20.28% |
| Q4 2017 | -17.11% |
| Q3 2017 | 8.68% |
| Q2 2017 | 70.07% |
| Q1 2017 | -352.83% |
| Q4 2016 | -30.69% |
| Q3 2016 | -7.42% |
| Q2 2016 | -46.27% |
| Q1 2016 | -11.81% |